SREBP targets such as fatty acid synthase and LDL-receptor are often found to be elevated in cancer cells, thus implicating SREBP in deregulated lipogenesis in cancer cells and targetting lipid supply serves as a potential target for anticancer therapy [139,140]. Here, FASN is linked to cancer.